Please assess the completion status of the following clinical trial:

Trial Title: Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed colorectal cancer~* Patients scheduled to receive mFOLFOX6 (in the adjuvant setting or for metastatic disease) as part of their chemotherapy regimen~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Life expectancy \> 6 months~* ANC ≥ 1,500/mm³~* Platelet count ≥ 100,000/mm³~* Serum creatinine ≤ 1.5 mg/dL~* Total bilirubin ≤ 1.5 times upper limit of normal (ULN)~* AST and ALT ≤ 2.5 times ULN (≤ 5 times ULN in the presence of liver metastases)~* Fertile patients must use effective contraception~* Negative pregnancy test~* Not pregnant or nursing~* No serious concomitant systemic disorders, including active infection that, in the opinion of the investigator, would compromise the patient's safety or ability to complete the study~* No altered mental status precluding understanding of the informed consent process and/or completion of the necessary studies~* Must be able to follow protocol requirements and give informed consent~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* Concurrent bevacizumab allowed~* No concurrent warfarin (Coumadin®)~  * Concurrent enoxaparin (Lovenox®) allowed~* No concurrent theophylline or aminophylline~* No chocolate beginning 12 hours before day 1 of each course and through the end of that course's fluorouracil continuous IV

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- mFOLFOX6 (Type: EXPERIMENTAL): Patients will receive cycle 1 of standard dose mFOLFOX6, with the same dose of mFOLFOX6 continued in subsequent cycles, once patient achieves the target AUC.~mFOLFOX 6 is a regimen comprised of Oxaliplatin + Leucovorin +5-Fluorouracil (FU)

Based on this trial design, predict the completion outcome and termination type (if applicable).